Cecile Gouttefangeas

Title: The Innovative Contributions of Cecile Gouttefangeas

Introduction

Cecile Gouttefangeas is a prominent inventor based in Tuebingen, Germany. She has made significant contributions to the field of immunotherapy, particularly in cancer treatment. With a total of 4 patents to her name, her work focuses on developing novel therapeutic approaches to enhance anti-tumor immune responses.

Latest Patents

One of her latest patents is titled "Powerful MHC-class II peptides derived from survivin." This invention relates to peptides, nucleic acids, and cells that are utilized in the immunotherapy of cancer. It specifically addresses survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, which can be used alone or in combination with other tumor-associated peptides. These peptides serve as active pharmaceutical ingredients in vaccine compositions designed to stimulate anti-tumor immune responses. The invention highlights three novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells, which can be effectively used in vaccine compositions.

Career Highlights

Cecile Gouttefangeas is currently associated with Immatics Biotechnologies GmbH, where she continues to advance her research in cancer immunotherapy. Her innovative work has positioned her as a key figure in the development of new therapeutic strategies aimed at improving patient outcomes in oncology.

Collaborations

Cecile collaborates with notable colleagues such as Stefan Stevanovic and Toni Weinschenk. Their combined expertise contributes to the advancement of research and development in the field of immunotherapy.

Conclusion

Cecile Gouttefangeas is a trailblazer in the realm of cancer immunotherapy, with her innovative patents paving the way for new treatment options. Her dedication to research and collaboration with esteemed colleagues underscores her commitment to improving cancer therapies.